Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 221 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intravenous immunoglobulins (IVIG) Clear all
Completed Phase 2Phase 3 Interventional Results available

A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia

NCT00194987
View directory record Official record
Conditions
Alloimmune Thrombocytopenia, Fetal Alloimmune Thrombocytopenia
Interventions
IVIG (Intravenous Immunoglobulin), prednisone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT00538915
View directory record Official record
Conditions
Primary Immune Deficiency Disorders (PIDD)
Interventions
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

NCT04634435
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
Combination Product
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 8, 2026, 6:45 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT07540221
View directory record Official record
Conditions
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions
Gamunex-C, Xembify
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

NCT00812565
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, octagam 10%
Drug · Biological
Lead sponsor
Octapharma
Industry
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hoboken, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 3 Interventional

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

NCT01406470
View directory record Official record
Conditions
Immunologic Deficiency Syndrome
Interventions
Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Birmingham, Alabama • North Palm Beach, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

NCT04566692
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IGSC 20%
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
6 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • North Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 8, 2026, 6:45 PM EDT
Recruiting Phase 4 Interventional

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

NCT06958796
View directory record Official record
Conditions
Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions
Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
Drug
Lead sponsor
Camille N. Kotton, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 8, 2026, 6:45 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

RECOVER-AUTONOMIC Platform Protocol

NCT06305780
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
50
States / cities
Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 8, 2026, 6:45 PM EDT
Terminated No phase listed Observational

Autoimmune Gastrointestinal Dysmotility: Symptoms, Pathogenesis and Treatment

NCT04859829
View directory record Official record
Conditions
Dysmotility Syndrome, Autoimmunity
Interventions
Current Intravenous Immunoglobulin (IVIG) treatment, No Intravenous Immunoglobulin (IVIG) treatment
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

NCT00419341
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Human Normal Immunoglobulin for Subcutaneous Administration
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 8, 2026, 6:45 PM EDT
Active, not recruiting Phase 3 Interventional

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

NCT04474223
View directory record Official record
Conditions
AVB - Atrioventricular Block, Fetal AVB
Interventions
Dexamethasone, IVIG
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia

NCT01350440
View directory record Official record
Conditions
Spinocerebellar Ataxia
Interventions
IVIG
Biological
Lead sponsor
University of South Florida
Other
Eligibility
10 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Post-bypass Prophylactic IVIG in Infants and Neonates

NCT02043379
View directory record Official record
Conditions
Hypogammaglobulinemia, Congenital Heart Disease
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 6 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 8, 2026, 6:45 PM EDT
Withdrawn Phase 2 Interventional

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

NCT04450654
View directory record Official record
Conditions
Immune-Mediated Necrotizing Myopathy
Interventions
Gamunex-C, Albumin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

NCT03939637
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT02465359
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Immune Globulin Subcutaneous (Human)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 8, 2026, 6:45 PM EDT
Terminated Not applicable Interventional Results available

Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT03772717
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
5 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)

NCT00001550
View directory record Official record
Conditions
Muscle Rigidity, Spasm, Stiff Man Syndrome
Interventions
IVIg
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2006 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy

NCT01522235
View directory record Official record
Conditions
Autoimmune Autonomic Ganglionopathy (AAG)
Interventions
Double blinded IVIg, Double blinded Placebo, Single Blinded IVIg
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 8, 2026, 6:45 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

NCT04565015
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
GC5107
Biological
Lead sponsor
GC Biopharma Corp
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Results available

Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

NCT04411667
View directory record Official record
Conditions
Sars-CoV2
Interventions
Octagam
Drug
Lead sponsor
George Sakoulas, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 8, 2026, 6:45 PM EDT
Completed Phase 3 Interventional

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

NCT00220766
View directory record Official record
Conditions
Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
Interventions
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 8, 2026, 6:45 PM EDT